Cargando…

Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis

BACKGROUND: Strategies for sequencing disease modifying therapies (DMTs) in multiple sclerosis (MS) patients include escalation, high efficacy early, induction, and de-escalation. OBJECTIVE: To provide a perspective on de-escalation, which aims to match the ratio of DMT benefit/risk in aging patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vollmer, Brandi L., Wolf, Andrew B., Sillau, Stefan, Corboy, John R., Alvarez, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821102/ https://www.ncbi.nlm.nih.gov/pubmed/35145470 http://dx.doi.org/10.3389/fneur.2021.799138

Ejemplares similares

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
por: Honce, Justin M., et al.
Publicado: (2020)

Serious safety events in rituximab‐treated multiple sclerosis and related disorders
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Evaluation of Plasma Neurofilament Light Chain Levels as a Biomarker of Neuronal Injury in the Active and Chronic Phases of Autoimmune Neurologic Disorders
por: Kammeyer, Ryan, et al.
Publicado: (2022)

Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions
por: Alvarez, Enrique, et al.
Publicado: (2022)

Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Piquet, Amanda L., et al.
Publicado: (2021)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
por: Simone, Isabella Laura, et al.
Publicado: (2021)

Multiple sclerosis and exercise—A disease-modifying intervention of mice or men?
por: Martin, Sarah-Jane, et al.
Publicado: (2023)

Therapeutic Benefits of Short-Arm Human Centrifugation in Multiple Sclerosis–A New Approach
por: Kourtidou-Papadeli, Chrysoula, et al.
Publicado: (2022)

Neural Processes of Psychological Stress and Relaxation Predict the Future Evolution of Quality of Life in Multiple Sclerosis
por: Meyer-Arndt, Lil, et al.
Publicado: (2021)

Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod—potentials and risks of subsequent highly active agents
por: Korsen, Melanie, et al.
Publicado: (2022)

Escalate and De-Escalate Therapies for Intracranial Pressure Control in Traumatic Brain Injury
por: Battaglini, Denise, et al.
Publicado: (2020)

Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review
por: Capone, Fioravante, et al.
Publicado: (2022)

Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies
por: Simoens, Steven
Publicado: (2022)

Serotonergic drug repurposing in multiple sclerosis: A new possibility for disease-modifying therapy
por: Melnikov, Mikhail, et al.
Publicado: (2022)

Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment
por: Jayaraman, Sundararajan, et al.
Publicado: (2022)

The Seasonal Fluctuation of Fatigue in Multiple Sclerosis
por: Grothe, Matthias, et al.
Publicado: (2022)

Comparing 16 Different Dual–Tasking Paradigms in Individuals With Multiple Sclerosis and Healthy Controls: Working Memory Tasks Indicate Cognitive–Motor Interference
por: Leone, Carmela, et al.
Publicado: (2020)

Predictors of Evolution Into Multiple Sclerosis After a First Acute Demyelinating Syndrome in Children and Adolescents
por: Papetti, Laura, et al.
Publicado: (2019)

Pelvic Floor Muscle Training and Its Benefits for Multiple Sclerosis Patients Suffering From Urinary Incontinence and Sexual Dysfunction
por: Sapouna, Vaia, et al.
Publicado: (2023)

Comorbidity in Multiple Sclerosis
por: Magyari, Melinda, et al.
Publicado: (2020)

The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses
por: Claflin, Suzi B., et al.
Publicado: (2019)

Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies
por: Sgarlata, Eleonora, et al.
Publicado: (2022)

Emerging therapies for treatment of multiple sclerosis
por: Corboy, John R, et al.
Publicado: (2010)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
por: Mirabella, Massimiliano, et al.
Publicado: (2022)

Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis
por: Altmann, Patrick, et al.
Publicado: (2021)

Cognitive Processes Underlying Verbal Fluency in Multiple Sclerosis
por: Delgado-Álvarez, Alfonso, et al.
Publicado: (2021)

Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis
por: Milstein, Joshua L., et al.
Publicado: (2019)

Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies
por: Bridge, Francesca, et al.
Publicado: (2023)

The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review
por: Kania, Karolina, et al.
Publicado: (2023)

Deciphering Multiple Sclerosis Progression
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

Editorial: Cognition in Multiple Sclerosis
por: Cortese, Rosa, et al.
Publicado: (2021)

Impact of Andropause on Multiple Sclerosis
por: Ysrraelit, Maria C., et al.
Publicado: (2021)

Therapeutic Advances in Multiple Sclerosis
por: Yang, Jennifer H., et al.
Publicado: (2022)

Editorial: Preventing multiple sclerosis
por: Dobson, Ruth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c3cqibh33te9219i6hbcodnq33